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Abstract
Background: Several recent reports have demonstrated that tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D)
(YMDD) motif mutations can naturally occur in chronic HBV patients without antiviral treatment such as lamivudine therapy.
This paper aims to assess the overall spontaneous incidence and related risk factors of YMDD-motif mutations among
lamivudine-naı ¨ve chronic HBV carriers, so as to provide some clue for clinical treatment of hepatitis B.
Methodology/Principal Findings: Chinese and English literatures were searched for studies reporting natural YMDD
mutations among untreated chronic HBV patients from 2001 to 2010. The incidence estimates were summarizedand analyzed
by meta-analyses. Forty-seven eligible articles from eight countries were selected in this review (13 in English and 34 in
Chinese). The pooled incidence of YMDD-motif mutation among untreated chronic HBV patients from eight countries was
12.21%(95% CI: 9.69%–14.95%). China had an incidence of 13.38% (95% CI: 10.90%–16.07%) and seven other countries had an
incidence of 9.90% (95% CI: 3.28%–19.55%), respectively. Lamivudine therapy would increase the risk of mutations 5.23 times
higher than the untreated patients. A higher HBV DNA copy numberwasassociated withincreased incidence of natural YMDD
mutation. No significant difference was found in YMDD mutation incidence between groups of different gender, age, HBeAg
status, patients’ ALT (alanine aminotransferase) level, and between the groups of HBV genotype B and C.
Conclusions: The YMDD-motif mutations can occur spontaneously with a relatively high incidence in CHB patients
untreated with lamivudine. These mutations might be the consequence of accumulated base mismatch due to the nature of
viral polymerase. More fundamental and clinical studies are needed to clarify the influence of YMDD mutations in hepatitis B
progression and antiviral treatment.
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Introduction
Hepatitis B virus (HBV) infection has long been a serious public
health problem around the world. HBV is one of the main causes
of acute and chronic hepatitis in humans. Nearly 400 million
people are infected chronically with HBV worldwide [1]. It has
been demonstrated that chronic infection with this virus is linked
to the development of cirrhosis and hepatocellular carcinoma,
accounting for 0.5–0.75 million deaths per year.
Antiretroviral treatment is the main clinical treatment of chronic
hepatitis B (CHB). Lamivudine, a nucleoside analogue, has been
widely used because of its high effectiveness. However, long-term
use of lamivudine may lead to the emergence of lamivudine-
resistance in some HBV cases. The resistance generation is closely
associated with mutations in the highly conserved YMDD motif,
which is in the catalytic domain C of viral DNA polymerase. The
YMDD motif has an amino acid sequence of tyrosine (Y)-
methionine (M)-aspartic acid (D)-aspartic acid (D) [2] and is both
the binding and functional site of lamivudine.
Recent reports revealed that besides the mutations caused by
lamivudine therapy, some YMDD mutations can occur sponta-
neously in lamivudine-untreated CHB patients. Because HBV
reverse transcriptase has no proofreading activity during the
replication process, mutations can naturally occur due to random
nucleotide misincorporation [3]. The most common substitutions
are methionine at amino acid position-204 to either isoleucine
(rtM204I, YIDD mutant) or valine (rtM204V, YVDD mutant)
[4,5]. Many studies have reported the incidence and characteristic
of spontaneous YMDD-motif mutation in lamivudine-naive CHB
patients. However, the reported incidences were quite different
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reviews the available publications, aiming to comprehensively
provide not only the incidence but also associated factors of
natural YMDD-motif mutation among lamivudine-untreated
CHB patients. The results should provide scientific evidences for
clinical treatment and future research of YMDD mutation.
Materials and Methods
Search strategy
A number of sources were used to access data for this review.
Published articles were searched in PubMed (http://www.ncbi.
nlm.nih.gov/pubmed) and Embase (http://www.embase.com/
search) database from January 2001 to December 2010 using
the search terms: YMDD, lamivudine, HBV OR hepatitis B,
spontaneous mutation OR natural mutation, untreated, and naive.
The two Chinese databases: China National Knowledge Infra-
structure (CNKI) (http://epub.edu.cnki.net/) and WanFang
(http://g.wanfangdata.com.cn/) were also searched for articles
related to HBV and YMDD motif mutation from January 2001 to
December 2010. The reference lists of relevant articles were also
searched manually for complement. This review was conducted
and reported according to the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) Statement
issued in 2009 (Table S1) [6].
Selection criteria
All the potentially relevant papers were reviewed independently
by two investigators through assessing the eligibility of each article
and useful data were extracted with standardized data-extraction
forms. Studies published in English and Chinese were eligible if
they fulfilled the following criteria: (1) studies in the mentioned
four databases with full text, or with available data in abstract; (2)
study objects contain CHB patients with NO treatment of
lamivudine or other antiviral drugs; (3) studies report the rates of
YMDD mutation among lamivudine-untreated CHB cases.
The exclusion criteria were: (1) studies without specific sample
origins; (2) studies with overlapping time intervals of the same
sample collection; (3) study objects were treated with lamivudine;
(4) study objects were patients with acute hepatitis B; (5) subset of a
published article by the same authors; (6) studies present unclear
data or obviously paradoxical data.
Data extraction and quality assessment
The following information, though some studies did not contain
all of them, were extracted from the literatures: first author’s
name, publication date, journal title, study area, sample size (the
number of CHB patients untreated with lamivudine), the number
of cases with YMDD mutation, the method of detecting YMDD
mutation, gender and average age of study objects, the status of
HBeAg (positive or negative), the amount of serum HBV DNA,
ALT (alanine aminotransferase) level, and HBV genotype. All the
numerical values of HBV DNA copies were converted to
logarithm. Two investigators (Keqin Ding and Yuhua Gong)
extracted and collected data independently using a standardized
data-extraction protocol. Any discrepancy was settled by consen-
sus of the whole team.
Statistical analysis
In this study, random effect model or fixed effect model was
used for meta-analysis, according to the heterogeneity between
studies which was tested with the Q test (P,0.10 was considered
indicative of statistically significant heterogeneity) and the I
2
statistic (values of 25%, 50% and 75% are considered to represent
low, medium and high heterogeneity respectively). The fixed effect
model was used when there was no significant heterogeneity
(I
2,50%); otherwise the random effect model was used. P values
were calculated by x
2 tests. All the reported P values are two-sided
and P values less than 0.05 were regarded as statistically significant
for all included studies.
Publication bias was examined by a funnel plot of log OR (odds
ratio) against its standard error using Begg’s test, and the degree of
asymmetry was tested statistically using Egger’s unweighed
regression asymmetry test. Publication bias exists if the rank
correlation coefficient from Begg’s test is close to 1, or the slope
parameter from Egger regression is high.
Data manipulation and statistical analyses were undertaken
using the Statistical Software Package (STATA) 10.0 (STATA
Corporation, College Station, TX, USA, 2009) and Review
Manager 4.2 (The Cochrane Collaboration, Oxford, United
Kingdom, 2003).
Results
According to the literature search strategies, a total of 202
studies (54 studies in PubMed and Embase, and 148 studies in
CNKI and Wanfang database) were identified, and 155 studies
were excluded based on the inclusion and exclusion criteria.
Finally there were 47 studies adopted in this study (13 studies in
English and 34 studies in Chinese) as showed in Figure 1 and
Figure S1 [6].
The studies of our review were involved in the following 18
provinces and municipalities in China and seven other countries:
Central China (Hubei, Hunan), North China (Beijing, Liaoning,
Jilin, Shan’xi), South China(Hainan, Guangdong, Guangxi), East
China (Shanghai, Shandong, Jiangsu, Zhejiang), Northwest China
(Shaanxi, Xinjiang), and Southwest China (Chongqing, Sichuan,
Yunnan); Japan, Korea, Iran, Italy, Turkey, Jordan, and South
Africa. A total of 4,555 CHB patients untreated with lamivudine
and other antiviral drugs were involved in this review. A great
majority of these cases were collected from hospitals.
Difference in the incidence of YMDD mutation between
lamivudine-treated cases and lamivudine-untreated
cases
Twelve studies compared YMDD mutation incidence between
611 lamivudine-treated CHB patients and 551 untreated CHB
patients. There was no significant statistical heterogeneity
(x
2=15.18, P=0.17, I
2=27.5%). The meta-analysis with fixed
effects models demonstrated higher YMDD mutation rate in
lamivudine-treated CHB cases than in untreated CHB cases
(OR=5.23, 95% CI: 3.55–7.71; Z=8.37, P,0. 01) (Figure 2).
Begg’s test and Egger’s test showed that publication bias existed.
Incidence of YMDD motif mutation among lamivudine-
untreated CHB patients
As showed in Table 1, the pooled incidence of all the eight
countries in YMDD mutation among lamivudine-untreated cases
is 12.21% (95% CI: 9.69%–14.95%), while the pooled incidence
in China is 13.38% (95% CI: 10.90%–16.07%). We also
calculated the incidence in each sub-region of China. The
naturally occurring YMDD mutation was relatively more severe
in Northwest China and Southwest China, where the incidences
were 20.19% (95% CI: 14.03%–27.10%) and 17.23% (95% CI:
6.07%–32.58%), respectively. The lowest incidence was in north
China with the rate of 6.71% (95% CI: 3.87%–10.26%). The
incidences of naturally occurring YMDD motif mutation in
Central China, East China, and South China were 12.77% (95%
Natural YMDD Mutation among Patients with HBV
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doi:10.1371/journal.pone.0032789.g002
Figure 1. Flow diagram of the systematic literature research.
doi:10.1371/journal.pone.0032789.g001
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Region Province Author Year
Untreated
patients
Cases of
YMDD
mutation
Incidence of
YMDD mutation
(95%CI )(%)
Pooled
incidence
(95%CI)(%)
Weight
(%)
China Central China Hubei Xiang T [7] 2010 40 3 8.51 ( 2.02, 18.84) 12.77 ( 7.06, 19.87) 7.10
Wei J [8] 2010 449 46 10.35 ( 7.69, 13.31)
Hunan Tang XL [9] 2009 119 23 19.59 ( 13.01, 27.14)
North China Liaoning Shi M [10] 2006 98 5 5.54 ( 1.92, 10.87) 6.71 ( 3.87, 10.26) 8.34
Shan’xi Qi QS [11] 2005 36 2 6.68 ( 1.01, 16.85)
Jilin Xiong Y [12] 2008 30 1 4.70 ( 0.18, 14.77)
Beijing Ren YQ [13] 2004 65 6 9.84 ( 3.89, 18.10)
East China Shandong Wu C [14] 2007 38 3 8.93 ( 2.13, 19.75) 11.18 ( 8.34, 14.35) 30.30
Shanghai Wang JF [15] 2003 90 6 7.14 ( 2.78, 13.28)
Min XC [16] 2009 196 21 10.90 ( 6.96, 15.63)
Huo H [17] 2006 183 40 22.02 ( 16.33, 28.26)
Jiangsu Yu HZ [18] 2009 20 2 11.79 ( 1.87, 28.62)
Qian JB [19] 2002 86 3 4.01 ( 0.93, 9.10)
Qiu YW [20] 2008 380 63 16.66 ( 13.11, 20.55)
Cheng NL [21] 2008 170 14 8.48 ( 4.78, 13.11)
Zhejiang Zhang JM [22] 2004 122 12 10.17 ( 5.47, 16.11)
Zheng JM [23] 2003 40 3 8.51 ( 2.02, 18.84)
Cheng FJ [24] 2006 89 12 13.90 ( 7.56, 21.74)
Zheng NH [25] 2007 229 16 7.17 ( 4.20, 10.84)
Yan MH [26] 2003 110 19 17.57 ( 11.09, 25.16)
South China Hainan WU J [27] 2009 49 7 14.99 ( 6.56, 26.08) 14.91 ( 8.04, 23.41) 16.03
Guangxi Huang ZM [28] 2005 104 28 27.14 ( 19.12, 36.00)
Qian YQ [29] 2005 125 30 24.22 ( 17.15, 32.02)
Guangdong QU YY [30] 2006 140 20 14.52 ( 9.22, 20.79)
Liu jH [31] 2008 176 7 4.22 ( 1.77, 7.69)
Guo HB [32] 2004 29 6 21.65 ( 9.02, 37.88)
Yu J [33] 2007 71 4 6.24 ( 1.87, 12.94)
NorthWest Xinjiang Li CM [34] 2003 39 3 8.71 ( 2.07, 19.27) 20.19 ( 14.03, 27.10) 13.80
Zhang XH [35] 2003 150 32 21.53 ( 15.34, 28.40)
Shaanxi Qu JX [36] 2010 82 21 25.91 ( 17.11, 35.81)
Qu JX [37] 2008 106 28 26.65 ( 18.72, 35.38)
Pan HQ [38] 2010 110 31 28.40 (20.43, 37.11)
Zhang Y [39] 2005 60 5 8.99 ( 3.17, 17.38)
SouthWest Chongqing Li L [40] 2005 54 11 20.92 ( 11.28, 32.54) 17.23 ( 6.07, 32.58) 8.06
Liu TH [41] 2004 55 3 6.22 ( 1.46, 13.97)
Sichuan He X [42] 2007 12 1 11.25 ( 0.49, 33.19)
Yunnan Wang YQ [43] 2009 190 60 31.70 ( 25.30, 38.42)
Pooled incidence of YMDD mutation in China 13.38 ( 10.90, 16.07) 83.63
Other
countries
Japan Matsuda M [44] 2004 20 1 6.96 ( 0.28, 21.36) 9.90 ( 3.28, 19.55) 16.37
Seta T [45] 2000 10 0 2.32 ( 2.02, 18.80)
Kobayashi S [46] 2001 18 5 28.89 (11.31, 50.71)
Korea Heo J [47] 2004 40 3 8.51 ( 2.01, 18.84)
Iran AB-Olyaee S [48] 2008 147 0 0.17 ( 0.16, 1.47)
Ramezani A [49] 2008 77 0 0.32 ( 0.29, 2.78)
Italy Villa E [50] 2009 11 0 2.13 ( 1.85, 17.34)
Turkey Akarsu M [51] 2006 71 13 18.76 ( 10.65, 28.53)
Jordan Masaadeh HA[52] 2008 4 1 29.48 ( 1.84, 71.94)
South Africa Selabe SG [53] 2007 15 3 21.78 ( 5.67, 44.52)
Pooled incidence of YMDD mutation in these eight countries 12.21 ( 9.69, 14.95) 100.00
doi:10.1371/journal.pone.0032789.t001
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14.91% (95% CI: 8.04%– 23.41%), respectively. In addition, the
pooled incidence of the seven foreign countries was 9.90% (95%
CI: 3.28%–19.55%).
Incidence of natural YMDD mutation between gender
and age
Stratified analyses showed that natural YMDD mutation was
not associated with gender (Figure 3) and age (Figure 4).
Eleven studies contained the available information of
gender distribution, including 967 males and 252 females. There
was no significant statistical heterogeneity (x
2=5.52, P=0.85,
I
2=0). Males and females had equal chances of natural YMDD
mutation (OR=1.12, 95% CI: 0.76–1.64; Z=0.57, P=0.57)
(Figure 3). No significant publication bias was observed in this
analysis.
The average age was mentioned in six studies including 177
cases with YMDD mutations and 702 cases without YMDD
mutation. Statistical heterogeneity was observed between groups
(x
2=66.00, P,0.00001, I
2=92.4%). By using the random effects
models, no significant difference of average age was showed
between groups (WMD (weighted mean difference)=23.73, 95%
CI: 211.49–4.03; Z=0.94, P=0.35) (Figure 4). Begg’s test and
Egger’s test indicated that publication bias existed.
Relation of natural YMDD mutation with pathogen-
related characteristics
Statistical analyses also showed that the occurrence of YMDD
mutation was not associated with HBeAg status (Figure 5), HBV
genotype (Figure 6), and ALT level (Figure 7). However, viral load
was showed to be associated with YMDD mutation. Neither
statistical heterogeneity nor publication bias was observed in those
Figure 3. Difference in the incidence of YMDD mutation between male and female patients.
doi:10.1371/journal.pone.0032789.g003
Figure 4. Difference in average ages between the patients with YMDD mutations and the patients without mutation.
doi:10.1371/journal.pone.0032789.g004
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genotype analysis.
Twelve studies including 1194 HBeAg-positive cases and
639 HBeAg-negative cases showed that the incidence of natural
YMDD-motif mutation was the same in different HBeAg status
groups (OR=1.03, 95% CI: 0.67–1.58; Z=0.15, P=0.88). It also
seems that ALT level did not play a role in occurrence of natural
YMDD mutation among patients with or without lamivud-
ine therapy (WMD=20.04, 95% CI: 23.23–3.14; Z=0.03,
P=0.98). Six studies reported 149 genotype-B HBV cases and 382
genotype-C HBV cases. No significant difference was found in
rates of natural YMDD mutation between genotype B and
genotype C (OR=1.62, 95% CI: 0.99–2.64; Z=1.92, P=0.05).
Eight studies (including 129 mutants and 774 cases without
mutation) referred to the relation of HBV-DNA viral load with
YMDD mutation. As showed in Figure 8, the HBV DNA copy
number was higher in the group with YMDD mutation than in the
group without mutation (WMD=0.27, 95% CI: 0.10–0.45;
Z=3.09, P=0.002).
Discussion
The application of lamivudine is a breakthrough in viral
treatment. Most patients with chronic hepatitis B had excellent
response to lamivudine, but development of YMDD mutants
attenuated efficacy of lamivudine treatment. Based on the studies
included in this analysis, lamivudine treatment increased the risk
of YMDD mutation to 5 fold of untreated controls (OR=5.23,
95% CI: 3.55–7.71). Although mutations in YMDD motif
increased during lamivudine treatment, many studies reported
that this mutation could also be spontaneous. As showed in this
report, the pooled incidence of natural YMDD mutation was as
high as 12.21% (95% CI: 9.69%–14.95%). This result mostly
represented the current situation in East Asia, especially China,
Figure 5. Difference in the incidence of YMDD mutation between HBeAg positive and HBeAg negative patients.
doi:10.1371/journal.pone.0032789.g005
Figure 6. Difference in the incidence of YMDD mutation between patients with HBV genotype B and genotype C.
doi:10.1371/journal.pone.0032789.g006
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from other 7 countries including Japan and Korea. It is not strange
because China has a high prevalence of HBV and numbers
of reports have been accumulated with clinical observation
of YMDD mutations. However, the incidence of spontaneous
YMDD mutations did not differ among countries (Table 1).
Gender and age were not related with spontaneous YMDD
mutations either (Figure 3 or Figure 4). These results suggest that
pathogen factors rather than host genetic factors are the
determinants of these natural YMDD mutants.
Ofallthepathogen-relatedfactorsstudiedinthisreview,viralload
was correlated with the incidence rate of natural YMDD mutation,
while patients’ HBeAg status and ALT level had no influence. A
cohort study by Atkins M et al. reported that mutant virus strains
were morelikely to appear inlamivudine-treated patients with larger
virus amount and longer therapy duration [54]. It seems like the
YMDD mutation might occurat certain rate and accumulate during
HBV replication. The relation between YMDD mutation and
infection duration was not conclusive because it is difficult to
determine the accurate infection duration. It is also hard to define a
proper study interval. Min XC et al [16] found no difference in
YMDD natural mutation between the group with 30-year or more
infection duration and the group with less than 30-year duration.
The issue is that 30-year duration may not be an appropriate study
interval to detect accumulation effect of mutations.
Hepatitis B virus has eight genotypes classified from A to H,
which variant in geographic distribution and characteristics.
Genotypes B and C are predominant in East Asia such as China,
Korea, and Japan [55]. A few reports showed an association
between emergence rate of YMDD mutants and HBV genotypes.
Huang ZM et al [28] demonstrated that the mutations mostly
occur in genotype C and its mixed genotypes. Controversially Min
XC et al [16] and Huo H et al [17] indicated these mutants
emerge more frequently in genotype B virus than in genotype C
virus. By this meta-analysis, no significant difference was observed
in incidence of YMDD mutation between genotype B and
genotype C. Due to inadequate information in the adopted
literatures we failed to analyze the other genotypes in this review.
Multinational studies would be valuable to clarify the relationship
between the occurrence of YMDD mutants and HBV genotypes.
It has been commonly recognized that YMDD mutations can
occur spontaneously. There are two major concerns following the
Figure 7. Difference in ALT level between the patients with YMDD mutations and the patients without mutation.
doi:10.1371/journal.pone.0032789.g007
Figure 8. Difference in HBV DNA copies between the patients with YMDD mutations and the patients without mutation.
doi:10.1371/journal.pone.0032789.g008
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the nature course of hepatitis B and worsen patients’ condition?
Secondly, since lamivudine treatment increases YMDD mutations,
is efficacy of lamivudine reduced during treatment? Currently
there is no evidence that YMDD mutations are associated with
ALT level. The result indicates that at least naturally existing
YMDD mutants may not worsen patients’ liver function. Alien MI
et al [4] demonstrated that the sensitivity of YMDD mutant strains
to lamivudine declined and viral titers rebounded during
lamivudine treatment in vitro. This finding does not mean
necessarily that patients with pre-existing mutations have to be
identified for special care or other therapy, because YMDD
mutants were found to be attenuated in replication capacity and
pathogenicity [44,46]. In that case, YMDD mutants have little
possibility to be dominant during infection and lamivudine should
still be effective to treat hepatitis. All these opinions are not
convincing enough to manipulate strategy of current lamivudine
treatment and more fundamental and clinical evidences are
needed to reveal the ultimate impact of YMDD mutations.
Considering the YMDD mutations could be acquired from
other people instead of occur spontaneously, the natural mutation
rate might be overestimated. However, there has been no
laboratory evidence clarifying this possibility. Qu JX et al [36]
indicated that children had higher mutation prevalence if YMDD
mutants were detected in their parents. The question is that
whether these mutants are transmitted from parents or genetic
background increases mutation rate. Plus the conclusion was
drawn from fourteen families and might just be a coincidence.
Further studies are needed to distinguish acquired mutation from
spontaneous mutation, including comparison of infectivity be-
tween the wild type and mutant virus strains, transfection assay of
cells, and animal experiments.
In conclusion, YMDD-motif mutation can occur naturally with
a rather high rate about 12.21% among untreated CHB patients.
Patients’ viral load is the factor that is admitted by majority to be
correlated with mutation rate. Further mechanism researches are
required to clarify the behaviors of mutants in addition to
attenuated replication ability. Large-scale population studies in
multi countries are also necessary to evaluate the influence of
YMDD mutations in hepatitis B progression and antiviral
treatment.
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